Иммуносенесценция как причина индивидуализированной иммуносупрессивной терапии при трансплантации почки

Трансплантация пожилому реципиенту, очевидно, более сложна из-за существующих сопутствующих заболеваний, изменений фармакокинетики иммуносупрессивных препаратов, полипрагмазии и трансформации иммунореактивности (иммуносенесценции). В обзоре представлены данные о модификации адаптивного и врожденного иммунитета при старении и рассмотрена возможность как сокращенной, так и адаптированной иммуносупрессивной терапии у пожилых реципиентов почечных трансплантатов для достижения оптимального баланса между эффективностью и осложнениями.

1. Hod T, Goldfarb-Rumyantzev AS. Clinical issues in renal transplantation in the elderly. Clin Transplant. 2015; 29 (2): 167–175. doi: 10.1111/ctr.12481.

2. Reese PP, Shults J, Bloom RD, Mussell A, Harnay MN, Abt P et al. Functional status, time to transplantation, and survival benefit of kidney transplantation among wait-listed candidates. Am J Kidney Dis. 2015; 66 (5): 837–845. doi: 10.1053/j.ajkd.2015.05.015.

3. Panchal H, Muskovich J, Patterson J, Schroder PM, Ortiz J. Expanded criteria donor kidneys for retransplantation United Network for Organ Sharing update: proceed with caution. Transpl Int. 2015; 28 (8): 990–999. doi: 10.1111/tri.12584.

4. Tsapepas DS, Vasilescu R, Tanriove B, Coppleson Y, Rekhtman Y, Hardy MA et al. Preformed donor-specific antibodies and risk of antibody-mediated rejection in repeat renal transplantation. Transplantation. 2014; 97 (6): 642–647. doi: 10.1097/01.TP.0000440954.14510.6a.

5. Aufhauser DD Jr, Peng AW, Murken DR, Concors SJ, Abt PL, Sawinski D et al. Impact of prolonged dialysis prior to renal transplantation. Clin Transplant. 2018; 32 (6): e13260. doi: 10.1111/ctr.13260.

6. Маркелова ЕВ, Хачатрян ЛС, Бирко ОН, Байбарина ЕВ. Показатели иммунного статуса у пациенток разных возрастных групп. Современные проблемы науки и образования. 2018; (6): 44.

7. Talamantes E, Norris KC, Mangione CM, Moreno G, Waterman AD, Peipert JD et al. Linguistic Isolation and Access to the Active Kidney Transplant Waiting List in the United States. Clin J Am Soc Nephrol. 2017; 12 (3): 483–492. doi: 10.2215/CJN.07150716.

8. Dreyer GJ, Hemke AC, Reinders MEJ, de Fijter JW. Transplanting the elderly: balancing aging with histocompatibility. Transplant Rev (Orlando). 2015; 29 (4): 205–211. doi: 10.1016/j.trre.2015.08.003.

9. Segall L, Nistor I, Pascual J, Mucsi I, Guirado L, Higgins R et al. Criteria for and Appropriateness of Renal Transplantation in Elderly Patients With End-Stage Renal Disease: A Literature Review and Position Statement on Behalf of the European Renal AssociationEuropean Dialysis and Transplant Association Descartes Working Group and European Renal Best Practice. Transplantation. 2016; 100 (10): 55–65. doi: 10.1097/TP.0000000000001367.

10. Hart A, Smith JM, Skeans MA, Gustafson SK, Wilk AR, Castro S et al. OPTN/SRTR 2018 Annual Data Report: Kidney. Am J Transplant. 2020; Suppl s1: 20–130. doi: 10.1111/ajt.15672.

11. Anzdata.org.au [Internet]. The 39th Annual ANZDATA Report Chapter 8: Transplantation 2016. [updated 2016 Jan; cited 2020 Dec 12]. Available from: https://www.anzdata.org.au/report/anzdata-39th-annual-report-2016.

12. Pippias M, Stel VS, Abad Diez JM, Afentakis N, Jose Antonio Herrero-Calvo JS, Ariaset M et al. Renal replacement therapy in Europe: a summary of the 2012 ERAEDTA Registry Annual Report. Clin Kidney J. 2015; 8 (3): 248–261. doi: 10.1093/ckj/sfv014.

13. Готье СВ, Хомяков CМ. Донорство и трансплантация органов в Российской Федерации в 2018 году. XI сообщение регистра Российского трансплантологического общества. Вестник трансплантологии и искусственных органов. 2019; 21 (3): 7–32. doi: 10.15825/1995-1191-2019-3-7-32.

14. Шмарина НВ, Дмитриев ИВ, Хубутия БЗ, Пинчук АВ. Трансплантации почек от доноров c расширенными критериями пожилым реципиентам в НИИ СП им. Н.В. Склифосовского. Трансплантология. 2018; 10 (3): 175–184. doi: 10.23873/2074-0506-2018-10-3-175-184.

15. Maggiore U, Abramowicz D, Budde K. Renal transplantation in the elderly. Transplant Rev (Orlando). 2015; 29 (4): 191–192. doi: 10.1016/j.trre.2015.09.003.

16. Aubert O, Kamar N, Vernerey D, Viglietti D, Martinez F, Jean-Paul Duong-Van-Huyen JP et al. Long term outcomes of transplantation using kidneys from expanded criteria donors: prospective, population based cohort study. BMJ. 2015; 351: h3557. doi: 10.1136/bmj.h3557.

17. Usrds.org [Internet]. United States Renal Data System. 2016 USRDS Annual Data Report: Epidemiology of kidney disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2016. [updated 2016 Jan; cited 2020 Nov 22]. Available from: https://www.usrds.org/annual-data-report/previous-adrs/.

18. Le Meur Y. What immunosuppression should be used for old-to-old recipients? Transplant Rev (Orlando). 2015; 29 (4): 231–236. doi: 10.1016/j.trre.2015.08.004.

19. Cossart AR, Cottrell NW, Campbell SB, Isbel NM, Staatz CE. Characterizing the pharmacokinetics and pharmacodynamics of immunosuppressant medicines and patient outcomes in elderly renal transplant patients. Transl Androl Urol. 2019; 8 (Suppl 2): S198–S213. doi: 10.21037/tau.2018.10.16.

20. Gupta R, Schlendorf K, Lindenfeld J. Older and Wiser: Personalized Immunosuppression in the Current Era. JACC Heart Fail. 2017; 5 (12): 943–945. doi: 10.1016/j.jchf.2017.10.010.

21. Lund LH, Edwards LB, Dipchand AI, Goldfarb S, Kucheryavaya AY, Levvey BJ et al. The Registry of the International Society for Heart and Lung Transplantation: Thirty-third Adult Heart Transplantation Report – 2016; Focus Theme: Primary Diagnostic Indications for Transplant. J Heart Lung Transplant. 2016; 35 (10): 1158– 1169. doi: 10.1016/j.healun.2016.08.017.

22. Colvin MM, Smith CA, Tullius SG, Goldstein DR. Aging and the immune response to organ transplantation. J Clin Invest. 2017; 127 (7): 2523–2529. doi: 10.1172/JCI90601.

23. Tang JT, de Winter BC, Hesselink DA, Sombogaard F, Wang LL, van Gelder T. The pharmacokinetics and pharmacodynamics of mycophenolate mofetil in younger and elderly renal transplant recipients. Br J Clin Pharmacol. 2017; 83 (4): 812–822. doi: 10.1111/bcp.13154.

24. Zhang WQ, Vierling JM. Progress in Immunosuppressive Agents for Solid-Organ Transplantation. Tex Heart Inst J. 2019; 46 (1): 69–70. doi: 10.14503/THIJ-18-6746.

25. Martins PNA, Tullius SG, Markmann JF. Immunosenescence and immune response in organ transplantation. Int Rev Immunol. 2014; 33 (3): 162–173. doi: 10.3109/08830185.2013.829469.

26. Krenzien F, ElKahl A, Quante M, Biefer HRC, Hirofumi U, Gabardi S et al. A rationale for age-adapted immunosuppression in organ transplantation. Transplantation. 2015; 99 (11): 2258–2268. doi: 10.1097/TP.0000000000000842.

27. Klinger M, Banasik M. Immunological characteristics of the elderly allograft recipient. Transplant Rev (Orlando). 2015; 29 (4): 219–223. doi: 10.1016/j.trre.2015.07.002.

28. Nian Y, Minami K, Maenesono R, Iske J, Yang J, Azuma H et al. Changes of T-cell Immunity Over a Lifetime. Transplantation. 2019; 103 (11): 2227–2233. doi: 10.1097/TP.0000000000002786.

29. Tu W, Rao S. Mechanisms Underlying T Cell Immunosenescence: Aging and Cytomegalovirus Infection. Front Microbiol. 2016; 7: 2111. doi: 10.3389/ fmicb.2016.02111.

30. Pallikkuth S, de Armas L, Rinaldi S, Pahwa S. T Follicular Helper Cells and B Cell Dysfunction in Aging and HIV-1 Infection. Front Immunol. 2017; 8: 1380. doi: 10.3389/fimmu.2017.01380.

31. Palmer S, Albergante L, Blackburn CC, Newman TJ et al. Thymic involution and rising disease incidence with age. Proc Natl Acad Sci USA. 2018; 115 (8): 1883–1888. doi: 10.1073/pnas.1714478115.

32. Macallan DC, Borghans JAM, Asquith B. Human T Cell Memory: A Dynamic View. Vaccines (Basel). 2017; 5 (1): 5. doi: 10.3390/vaccines5010005.

33. Онищенко НА, Башкина ЛВ, Никольская АО, Артамонов СД. Информационная значимость мониторинга популяций CD4+ Т-лимфоцитов в диагностике и прогнозировании реакции организма на трансплантат. Вестник трансплантологии и искусственных органов. 2013; 15 (4): 112–125. doi: 10.15825/1995-1191-2013-4-112-125.

34. Denkinger MD, Leins H, Schirmbeck R, Florian MC, Geiger H. HSC Aging and Senescent Immune Remodeling. Trends Immunol. 2015; 36 (12): 815–824. doi: 10.1016/j.it.2015.10.008.

35. Schaenman JM, Rossetti M, Sidwell T, Groysberg V, Sunga G, Korin Y et al. Increased T cell immunosenescence and accelerated maturation phenotypes in older kidney transplant recipients. Hum Immunol. 2018; 79 (9): 659– 667. doi: 10.1016/j.humimm.2018.06.006.

36. Moro-García MA, Alonso-Arias R, Lopez-Larrea C. When Aging Reaches CD4+ T-Cells: Phenotypic and Functional Changes. Front Immunol. 2013; 4: 107. doi: 10.3389/fimmu.2013.00107.

37. Seyda M, Elkhal A, Quante M, Tullius SG. T Cells Going Innate. Trends Immunol. 2016; 37 (8): 546–556. doi: 10.1016/j.it.2016.06.004.

38. Neudoerfl C, Mueller BJ, Blume C, Daemen K, Stevanovic-Meyer M, Keil J et al. The Peripheral NK Cell Repertoire after Kidney Transplantation is Modulated by Different Immunosuppressive Drugs. Front Immunol. 2013; 4: 46. doi: 10.3389/fimmu.2013.0004.

39. Артемов ДВ, Зулькарнаев АБ, Ватазин АВ. Возрастные особенности субпопуляционного состава лимфоцитов и функциональной активности мононуклеаров периферической крови у больных хронической болезнью почек до и после трансплантации. Вестник трансплантологии и искусственных органов. 2020; 22 (1): 40–49. doi: 10.15825/1995-1191-2020-1-40-49.

40. Chou JP, Effros RB. T cell replicative senescence in human aging. Curr Pharm Des. 2013; 19 (9): 1680–1698.

41. Chen G, Lustig A, Weng NP. T cell aging: a review of the transcriptional changes determined from genome-wide analysis. Front Immunol. 2013; 4: 121. doi: 10.3389/fimmu.2013.00121.

42. Frasca D, Diaz A, Romero M, Landin AM, Blomberg BB. Age effects on B cells and humoral immunity in humans. Ageing Res Rev. 2011; 10 (3): 330–335. doi: 10.1016/j.arr.2010.08.004.

43. Goronzy JJ, Weyand CM. Understanding immunosenescence to improve responses to vaccines. Nat Immunol. 2013; 14: 428–436. doi: 10.1038/ni.2588.

44. Wang C, Liu Y, Xu LT, Jackson KJL, Roskin KM, Pham TD et al. Effects of aging, cytomegalovirus infection, and EBV infection on human B cell repertoires. J Immunol. 2014; 192 (2): 603–611. doi: 10.4049/jimmunol.1301384.

45. Gong Z, Liu T, Wan Y, Hang Z, Tong X, Zhang B et al. Decreased c-rel activation contributes to aberrant interleukin-2 expression in CD4+ T-cells of aged rats. Mol Immunol. 2014; 61 (1): 1–6. doi: 10.1016/j.molimm.2014.04.010.

46. Seyda M, Quante M, Uehara H, Slegtenhorst BR, Elkhal A, Tullius SG et al. Immunosenescence in renal transplantation: a changing balance of innate and adaptive immunity. Curr Opin Organ Transplant. 2015; 20 (4): 417–423. doi: 10.1097/MOT.0000000000000210.

47. Dias S, D’Amico A, Cretney E, Liao Y, Tellier J, Bruggeman C et al. Effector Regulatory T Cell Differentiation and Immune Homeostasis Depend on the Transcription Factor Myb. Immunity. 2017; 46 (1): 78–91. doi: 10.1016/j.immuni.2016.12.017.

48. Derhovanessian E, Chen S, Maier AB, Hahnel K, de Craen AJM, Roelofs H. CCR4+ Regulatory T Cells Accumulate in the Very Elderly and Correlate With Superior 8-Year Survival. J Gerontol A Biol Sci Med Sci. 2015; 70 (8): 917–923. doi: 10.1093/gerona/glu128.

49. Lehner LJ, Staeck O, Halleck F, Liefeldt L, Bamoulid J, Budde K. Need for optimized immunosuppression in elderly kidney transplant recipients. Transplant Rev (Orlando). 2015; 29 (4): 237–239. doi: 10.1016/j.trre.2015.08.001.

50. Weaver-Pinzon O, Edwards LB, Taylor DO, Kfoury AG, Drakos SG, Selzman CH et al. Association of recipient age and causes of heart transplant mortality: implications for personalization of post-transplant management – an analysis of the International Society for Heart and Lung Transplantation registry. J Heart Lung Transplant. 2017; 36 (4): 407–417. doi: 10.1016/j.healun.2016.08.008.

51. Shi YY, Hesselink DA, van Gelder T. Pharmacokinetics and pharmacodynamics of immunosuppressive drugs in elderly kidney transplant recipients. Transplant Rev (Orlando). 2015; 29 (4): 224–230. doi: 10.1016/j.trre.2015.04.007.

52. Jackson-Spence F, Gillott H, Tahir S, Nath J, Mytton J, Evison F et al. Balancing risks for older kidney transplant recipients in the contemporary era: a single-centre observational study. Eur Geriatric Med. 2017; 8 (1): 42–47. doi: 10.1016/j.eurger.2016.11.004.

53. Tullius SG, Tran H, Guleria I, Malek SK, Tilney NL, Milford E. The Combination of Donor and Recipient Age is Critical in Determining Host Immunoresponsiveness and Renal Transplant Outcome. Ann Surg. 2010; 252 (4): 662–674. doi: 10.1097/SLA.0b013e3181f65c7d.

54. Peeters LEJ, Andrews LM, Hesselink DA, de Winter BCM, van Gelder T. Personalized immunosuppression in elderly renal transplant recipients. Pharmacol Res. 2018; 130: 303–307. doi: 10.1016/j.phrs.2018.02.031.

55. Hoehn RS, Singhal A, Wima K, Sutton JM, Paterno F, Woodle ES et al. Effect of pretransplant diabetes on short-term outcomes after liver transplantation: a national cohort study. Liver Int. 2015; 35 (7): 1902–1909. doi: 10.1111/liv.12770.

56. Sansoni P, Vescovini R, Fagnoni FF, Akbar A, Arens R, Chiu YL et al. New advances in CMV and immunosenescence. Exp Gerontol. 2014; 55: 54–62. doi: 10.1016/j.exger.2014.03.020.

57. AlBugami M, Kiberd B. Malignancies: pre and post transplantation strategies. Transplant Rev (Orlando). 2014; 28 (2): 76–83. doi: 10.1016/j.trre.2013.12.002.

58. Hutchison LC, O’Brien CE. Changes in Pharmacokinetics and Pharmacodynamics in the Elderly Patient. J Pharm Pract. 2007; 20 (1): 4–12. doi: 10.1177/0897190007304657.

59. Langman LJ, Jannetto PJ. Individualizing Immunosuppressive Therapy for Transplant Patients. Clin Chem. 2016; 62 (10): 1302–1303. doi: 10.1373/clinchem.2016.260380.

60. Khan S, Loi V, Rosner MH. Drug-induced kidney injury in the elderly. Drugs Aging. 2017; 34 (10): 729–741. doi: 10.1007/s40266-017-0484-4.

61. Meier M, Bode W, Nitschke M, Wong W, Ison M, Kramer J et al. High rejection rates with low dose immunosuppression in old for old kidney transplantation. Transplantationsmedizin. 2011; 23: 118–126.

62. Oberbauer R, Bestard O, Furian L, Maggiore U, Pascual J, Rostaing L. Optimization of tacrolimus in kidney transplantation: New pharmacokinetic perspectives. Transplant Rev (Orlando). 2020; 34 (2): 100531. doi: 10.1016/j.trre.2020.100531.

63. Онищенко НА, Артамонов СД, Крашенинников МЕ, Башкина ЛВ, Никольская АО. Индивидуальная устойчивость стереотипов иммунного реагирования и современные возможности их диагностики при трансплантации органов (иммуно-физиологический анализ проблемы). Вестник трансплантологии и искусственных органов. 2013; 15 (2): 123–134. doi: 10.15825/1995-1191-2013-2-123-134.